Clinical Trials
48 trialsNCT00092222 2026-06-05
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT04840602 2026-06-05
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04002947 2026-06-03
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03789240 2026-03-03
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT00006436 2025-12-30
EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00923013 2025-08-08
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT00001337 2025-06-22
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00001379 2025-06-19
Treatment and Natural History Study of Lymphomatoid Granulomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01059786 2025-06-12
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT00602459 2023-05-22
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01092182 2023-04-27
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00005780 2023-01-31
Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00114738 2022-10-10
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01030900 2022-10-06
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00001563 2022-01-19
EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00267865 2020-06-01
Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00074490 2018-12-31
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00088881 2017-05-25
Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00324779 2015-09-25
Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00087425 2015-04-30
Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00433537 2014-10-30
Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00054639 2014-05-28
Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00098670 2014-05-21
Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00121199 2014-05-21
Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00109967 2014-04-17
CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00070447 2014-01-28
Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00258336 2014-01-10
Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01307592 2014-01-10
Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00053092 2013-12-18
Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005959 2013-12-04
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00058461 2013-10-08
Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00026182 2013-08-26
Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00974792 2013-08-26
Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00005609 2013-08-16
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00086775 2013-08-02
Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00337246 2013-08-02
Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00893477 2013-08-02
GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00896519 2013-08-02
GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00003554 2013-07-18
Rituximab in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00059904 2013-07-18
Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00079443 2013-07-01
FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00001586 2013-05-15
Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00026351 2013-02-04
Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00080847 2013-01-07
S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00301795 2013-01-07
Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00069966 2009-07-07
Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00001805 2008-03-04
A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00265928 2008-01-28
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated